维格列汀联合阿卡波糖治疗2型糖尿病的疗效及安全性

The efficacy and safety of vidldagliptin combined with acarbose in treating type 2 diabetes

目的:观察维格列汀联合阿卡波糖对2型糖尿病患者的疗效及其安全性。方法:选取78例2型糖尿病患者,随机平分成2组。予治疗组维格列汀联合阿卡波糖,对照组安慰剂联合阿卡波糖。12周后,观察相关指标与低血糖反应。结果:治疗后治疗组患者糖化血红蛋白(HbA1c)、空腹血糖(FBG)以及餐后2 h血糖(2 h PG)明显降低(P<0.05),而空腹C肽(FCP)、餐后2 h C肽(2 h CP)、空腹胰岛素(FINS)和餐后2 h胰岛素(2 h INS)水平较前增长(P<0.05)。且治疗组较对照组FBG、HbA1c降低,空腹C肽、餐后2 h C肽、FINS、2 h INS升高(P<0.05)。但在两组患者治疗前后的身体质量指数(BMI)均无统计学意义(P>0.05),且均未有明确肝肾损伤指标(P>0.05),均无低血糖反应。结论 :维格列汀联合阿卡波糖临床疗效优于安慰剂联合阿卡波糖,无明显不良反应,其临床应用价值较高。

Objective To observe the efficacy and safety of vildagliptin combined with acarbose in treating type 2 diabetes. Methods 78 patients with type 2 diabetes were divided into two groups to have additional vildagliptin combined with acarbose or acarbose combined with placebo. The clinical efficacy and adverse reactions after 12 weeks were investigated. Results In the treatment group, FBG, 2 h PG and HbA1C declined after treatment（P〈0.05） and FCP, 2 h CP, FINS and 2 h INS increased（P〈0.05）. Compared with the control group, FBG and HbA1c in the treatment group were reduced and owever, FCP, 2 h CP, FINS and2 h INS were increased more significantly（P〉0.05）. There was no difference in the incidence of overall BMI between the two groups（P〈0.05）. There were either liver and kidney damage（P〉0.05）, nor hypoglycemia.Conclusion Vildagliptin combined with acarbose is superior to Acarbose combined with placebo, and it produced no more untoward effect.